Background/Aims Cholestatic liver disease (CLD) is a pathological condition characterized by impaired bile formation, secretion, and excretion. However, the key pathophysiological mechanisms of CLD remain elusive, and therapeutic efficacy is unsatisfactory.
Methods We administered berberine (BBR) or dihydroberberine (dhBBR) in bile duct ligation-, ANIT-, and mdr2-/- CLD mouse models to evaluate the anti-CLD effect. We conducted fecal microbiota transplantation to determine the role of gut microbiota in BBR’s effect. We conducted a randomized, controlled clinical trial to evaluate the effects of BBR in patients with CLD.
Results Oral BBR alleviates cholestatic liver injury in multiple mouse models. Gut microbes can transform BBR into dhBBR, which suppresses 5-hydroxytryptamine (5-HT) production in gut enterochromaffin cells by antagonizing tryptophan hydroxylase 1 (TPH1) activity and downregulating Tph1 transcription. This further ameliorates CLD by interrupting the 5-HT/5-HTR axis. A clinical study validated that BBR improved blood biochemical indicators in patients with CLD and decreased 5-HT levels.
Conclusions BBR is transformed by gut microbiota to ameliorate CLD via inhibiting 5-HT, suggesting potential novel strategies for further clinical use.
Citations
Citations to this article as recorded by
Therapeutic modulation of the gut microbiota by traditional Chinese medicine in the management of cholestatic liver injury Xiyan Ding, Jiaming Wang, Yicui Wang, Huaming Xu, Yanxin Liu Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Impact of co-housing on anxiety- and depression-like behaviors in rats exposed to chronic unpredictable mild stress Nuerbiya Maimaitiming, Wenwen Zhong, Jing Zhang, Yuanyuan Ma, Huayong Shi, Xingheng Li Brain Research Bulletin.2026; 240: 111889. CrossRef
Evodiamine targets ZO-1 to ameliorate cholestatic liver disease: Intestinal homeostasis as the core mediator of gut-liver axis repair and bile acid metabolism remodeling Shuxin Yan, Yao Zhang, Qiqi Fan, Wenwen Jia, Yihang Dai, Xinlin Li, Shan Lu, Yuhan Sheng, Shuang Sun, Ruichao Lin, Yang Tang, Chongjun Zhao Phytomedicine.2026; 157: 158288. CrossRef
Berberine derivative C51 modulates cGAS-STING-TIM-3 axis to reverse immune evasion and inhibit lung cancer growth Yuyan Bao, Bing Hong, Kaiping Liu, Zhenjian Lin, Jie Zhou, Yaping Wu, Senfeng Mou, Yanjie Yu Cellular Signalling.2025; : 112258. CrossRef
Serum metabolomics identifies novel prognostic biomarkers in amanita poisoning Dan Zhu, Jie Zhong, Yarong Liu, Sicheng Zhang, Lianhong Zou Frontiers in Pharmacology.2025;[Epub] CrossRef
Probiotic-Derived Strain-Specific Metabolites Ameliorate Metabolic Dysfunction–Associated Steatotic Liver Disease through Modulation of the Gut-Liver Axis Sang Jun Yoon, Jieun Choi, Sung-Min Won, Jeong Seok Yu, Hee Young Kim, Hyun Chae Joung, In Gyu Park, Jung A Eom, Sang Hak Han, Do Yup Lee, Ki Tae Suk Probiotics and Antimicrobial Proteins.2026; 18(3): 4353. CrossRef
Hypertension and Long-Term Adverse Clinical Outcomes in MASLD: Sensitivity Analyses for Unmeasured or Uncontrolled Confounding Guiying Gao, Xiuhong Wang, Ruizhe Huang, Jing Cao Journal of Hepatology.2026;[Epub] CrossRef
Extracellular Vesicles: Orchestrators of Intrahepatic and Systemic Crosstalk in Metabolic Dysfunction-Associated Steatotic Liver Disease Yu Lei, Mei Liu, Xiang Tao Pharmaceutics.2026; 18(1): 116. CrossRef
Hydrogel-Based Therapeutic Strategies for Post-Cholecystectomy NAFLD: Targeting Bile Acid Signaling, Gut Microbiota, Inflammation, and Hepatic Fibrosis Georgiana-Andreea Marinescu, Alexandra-Daniela Rotaru-Zavaleanu, Emil-Tiberius Trasca, Elena-Irina Caluianu, Oana Taisescu, Andrei Gresita, Madalina Iuliana Musat, Dumitru Radulescu, Razvan Mercut, Citto-Iulian Taisescu Gels.2026; 12(2): 179. CrossRef
From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease Gianmario Forcina, Vittoria Frattolillo, Maria De Cesare, Assunta Floriano, Rosamaria Palma, Federica Casamassima, Mario Bartiromo, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1329. CrossRef
The trillions of commensal microorganisms living in the gut lumen profoundly influence the physiology and pathophysiology of the liver through a unique gut-liver axis. Disruptions in the gut microbial communities, arising from environmental and genetic factors, can lead to altered microbial metabolism, impaired intestinal barrier and translocation of microbial components to the liver. These alterations collaboratively contribute to the pathogenesis of liver disease, and their continuous impact throughout the disease course plays a critical role in hepatocarcinogenesis. Persistent inflammatory responses, metabolic rearrangements and suppressed immunosurveillance induced by microbial products underlie the pro-carcinogenic mechanisms of gut microbiota. Meanwhile, intrahepatic microbiota derived from the gut also emerges as a novel player in the development and progression of liver cancer. In this review, we first discuss the causes of gut dysbiosis in liver disease, and then specify the pivotal role of gut microbiota in the malignant progression from chronic liver diseases to hepatobiliary cancers. We also delve into the cellular and molecular interactions between microbes and liver cancer microenvironment, aiming to decipher the underlying mechanism for the malignant transition processes. At last, we summarize the current progress in the clinical implications of gut microbiota for liver cancer, shedding light on microbiota-based strategies for liver cancer prevention, diagnosis and therapy.
Citations
Citations to this article as recorded by
Probiotic-Derived Strain-Specific Metabolites Ameliorate Metabolic Dysfunction–Associated Steatotic Liver Disease through Modulation of the Gut-Liver Axis Sang Jun Yoon, Jieun Choi, Sung-Min Won, Jeong Seok Yu, Hee Young Kim, Hyun Chae Joung, In Gyu Park, Jung A Eom, Sang Hak Han, Do Yup Lee, Ki Tae Suk Probiotics and Antimicrobial Proteins.2026; 18(3): 4353. CrossRef
Global research trends in bacteriophage and gut microbiota: a bibliometric and visual analysis from 2012 to 2025 Hui-Fang Kuang, Xiong-Yilang Jiang, Song-Yan Tie, Kun Lian, Mu-Yi Hao, Hang Xu, Xiao Huang, Yi Yang, Qian Guo, Jie Li, Ling-Li Chen Frontiers in Microbiology.2026;[Epub] CrossRef
Cinobufagin as a Potential Intervention Against Liver Cancer—A Comprehensive Review Nicole Simone de Lima Coelho, Victória Dogani Rodrigues, Otávio Simões Girotto, Renato César Moretti Júnior, Vítor Engrácia Valenti, Maria Angélica Miglino, Mônica Duarte da Silva, Caio Sérgio Galina Spilla, Ana Luiza Decanini Miranda de Souza, Sandra Mar Pharmaceuticals.2026; 19(1): 158. CrossRef
Gut microbial signatures of advanced hepatocellular carcinoma and their potential diagnostic value Yan Wang, Zhen Yang, Chuang Liu, Yufeng Liu, Zhongyuan Bai, Wentao Miao, Tiantian Zhang, Yan Wang, Xiang Li, Zhiyong Lai, Jun Xu Frontiers in Microbiology.2026;[Epub] CrossRef
Exploratory Analysis of Gut Microbiome and Metabolic Profile Changes Following Lenvatinib and Anti-PD-1 Combination Therapy in Liver Cancer Rui Zhong, Zhikun Lin, Binghui Jin, Xiaolin Wang, Hua Mu, Jinlong Hu, Qi Li, Peng Dou, Xinyu Liu, Chunxiu Hu, Guowang Xu, Guang Tan Metabolites.2026; 16(2): 97. CrossRef
Epistemic compression in large language model explanations of the gut–liver axis Man Sun, Dan Zang, Huan Zhou, Yi-Lin Che, Jun Chen Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Gut microbiota-mediated oncogenesis in hepatocellular carcinoma: a new avenue for therapeutic intervention Aswathi Ramesh, Rajasekaran Subbarayan, Dhasarathdev Srinivasan, Ranjith Balakrishnan, Rupendra Shrestha, Ankush Chauhan International Journal of Surgery.2026; 112(2): 4725. CrossRef
Normal weight obesity and the risk of liver cancer in 0.3 million Chinese adults: a prospective multicenter cohort study Chun-Rui Wang, Wei-Hong Huang, Zhang-You Guo, Chen-Wei Tang, Xin Dai, Ling-Xiang Xu, Guo-Chao Zhong International Journal of Surgery.2026; 112(2): 3530. CrossRef
The intratumoral microbiome in colorectal cancer: origins, microenvironmental interactions, and new horizons in precision medicine Xuemei Li, Qian Wang, Qiang Yuan, Li Wang Frontiers in Immunology.2026;[Epub] CrossRef
Effects of tacrolimus treatment on the gut microbiota and metabolites in liver transplant recipients Guohui Wang, Lu Liu, Hanshu Zhang, Panpan Mao, Saijuan Lu, Xiaofang Zhang, Xingde Li, Cangsang Song, Nikhilesh Anand PLOS One.2026; 21(2): e0343817. CrossRef
The Polyphenol–Microbiota Axis: Molecular Mechanisms, Metabolic Pathways, and Therapeutic Perspectives in Human Health Andrea Ballini, Simona Nicole Barile, Alfredo De Rosa, Maria Eleonora Bizzoca, Mariarosaria Boccellino, Salvatore Scacco, Stefania Cantore, Lorenzo Lo Muzio, Francesco Massimo Lasorsa, Roberto Arrigoni Journal of Personalized Medicine.2026; 16(3): 142. CrossRef
Intestinal-hepatic axis-mediated hepatocarcinogenesis and traditional Chinese medicine intervention strategies Lulu Song, Ying Zhou, Zhajun Zhan, Libin Pan, Luo Fang Pharmacological Research - Modern Chinese Medicine.2026; 19: 100790. CrossRef
Associations among physical activity, diet, non-lifestyle characteristics and the gut microbiome of cancer patients: A scoping review and network analysis Jerry Armah, Sarah Alzahid, Qinglin Pei, Lakeshia Cousin, Dany Fanfan, Coy Heldermon, Debra Lyon Oncoscience.2026; 13: 85. CrossRef
Microbiome and metabolite signatures for cirrhosis to HCC risk stratification: progress, controversies, and gaps Yanan Duan, Mengting Yang, Miaomiao Li, Yu Sun, Shiguo Liu Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Mucosal immunity in cancer metastasis: roles, mechanisms, and therapeutic implications Yaru Miao, Dongdong Cui, Yanghui Bi, Ruiping Zhang Frontiers in Immunology.2026;[Epub] CrossRef
Harnessing the gut microbiota in extra-intestinal cancers: from causal evidence to immunotherapy strategies Elisa Mattavelli, Valentina Da Prat, Salvatore Corallo, Alice Tartara, Simone Figini, Francesca De Simeis, Sofia Marino, Anna Uggè, Riccardo Caccialanza, Paolo Pedrazzoli, Angioletta Lasagna Immunotherapy.2026; 18(3): 223. CrossRef
The modern perspective on the role of microbiota in childhood chemotherapy Almaz Kh. Islamgulov, Azat A. Murtazin, Viktor A. Malievsky, Linara R. Kalmeteva, Dilyara D. Prolygina, Gulshat A. Davletbaeva, Gulnara R. Gazizullina Russian Journal of Oncology.2026;[Epub] CrossRef
Aging promotes the mitochondrial contact site and cristae organizing system complex dysfunction in metabolic-associated steatotic liver disease: A narrative review Bislom C. Mweene, Sepiso K. Masenga, Prasanna Katti, Prasanna Venkhatesh, Kit Neikirk, Andrea Marshall, Berwin Singh Swami Vetha, Ron McMillian, Annet Kirabo, Joyonna Gamble-George, Benjamin Rodriguez, Mohd Mabood Khan, Antentor Hinton Aging Advances.2026;[Epub] CrossRef
From dysbiosis to malignancy: decoding gut-driven pathways to clinical management in hepatocellular carcinoma Abdulrahman Ismaiel, Mhd Bashir Almonajjed, Mahdi Wardeh, Ahmed Abdelghafar, Stefan-Lucian Popa, Cristina Sabo, Dan L. Dumitrascu Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Polysaccharides-gut microbiota interaction: mechanisms regulating the hepatocellular carcinoma immune microenvironment Wei Peng, Kai Xiong, Yuyang Zheng, Jiahan Zheng, Yuanyuan Zhong, Jihao Yang, Yuchuan Jiang Frontiers in Immunology.2026;[Epub] CrossRef
Bacterial Extracellular Vesicles as Systemic Messengers: Integrating Their Roles in Gut-Liver-Brain Communication and Disease Farzaneh Hasanian-Langroudi, Hessam Yaghmaei, Erfan Soroush, Hamidreza Talifar, Maryam Meskini, Seyed Davar Siadat Probiotics and Antimicrobial Proteins.2026;[Epub] CrossRef
Selenium-enriched Tibetan kefir grain-fermented goji juice attenuates patulin-induced liver injury and is associated with gut microbiota modulation in mice Yifan Cheng, Jinyi Yang, Jinyue Xu, Xuejun Zeng, Kewei Feng, Yahong Yuan, Tianli Yue Food & Function.2026;[Epub] CrossRef
Gut Microbiota and the Gut–Liver Axis in Liver Disease: From Chronic Viral Hepatitis to Cirrhosis, Hepatocellular Carcinoma, and Microbiome-Based Therapies Sniedze Laivacuma, Olga Oblate, Aleksejs Derovs Microorganisms.2025; 13(5): 1053. CrossRef
Deciphering the circadian rhythm in colorectal cancer: a bibliometric analysis of research landscape and trends Linzi Chen, Zhongjie Wang, Ningkun Xiao, Jinhui Liu, Yuhan Tao, Sifang Zhang Frontiers in Oncology.2025;[Epub] CrossRef
Mechanism of activation of the Nrf2-Keap1 pathway by fermented Chinese herbal medicines via the gut-liver axis to alleviate cadmium-induced hepatotoxicity Li Jiang, Qiuhong Wu, Yilei Liang, Zhiwen Yang, Guang Fan, Pan Zhou, Xinyue Liu, Yachao Wang Environmental Chemistry and Ecotoxicology.2025; 7: 1300. CrossRef
Associations between the effectiveness of sleeve gastrectomy and the composition and function of gut microbiome in obese rats Yifan Cao, Songhan Qin, Dandan Liu, Tao Zhang, Yin Wu, Ming Xie, Jiwei Wang Journal of Gastrointestinal Surgery.2025; 29(9): 102153. CrossRef
Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Claudio Basile, Carlo Palma, Paolo Vaia, Marcello Dallio, Alessandro Federico Diabetology.2025; 6(8): 79. CrossRef
The microbiome–cancer axis as a hidden contributor to early-onset tumorigenesis Azfar Jamal, Mohammad Azhar Kamal, Yaser E. Alqurashi, Esam S. Al-Malki, Mohammed M. Naiyer, Syed Arif Hussain, Haroonrashid M. Hattiwale Medical Oncology.2025;[Epub] CrossRef
Tumor microenvironment and macroenvironment: A new perspective on holistic oncology Qun Chen, Kuirong Jiang, Michael S. Bronze, Min Li, Courtney W. Houchen, Yuqing Zhang Cancer Letters.2025; 634: 218076. CrossRef
Gut–liver axis dysregulation and microbial dysbiosis in invasive liver abscess: a narrative review Xiaoshuai Bai, Zhen Wang, Kai Guo, Ping Zhou, Lei Shi Frontiers in Immunology.2025;[Epub] CrossRef
The role of hypothyroidism in cirrhosis pathogenesis: A retrospective cohort study and multi-omics integration analysis Ziyang Yang, Weixuan Liang, Qi Zhang, Can Weng, Hao Deng, Zhuofeng Wen, Jingyi Wu, Jingwen Deng, Zhixin Xie, Yiwei Lin, Xiuling Fu, Chengxin Gu, Tao Yang, Hui Yang, Jiyuan Zhou, Renato Polimanti PLOS Genetics.2025; 21(11): e1011947. CrossRef
Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma Muhammad Masroor Hussain, Bi Feng, Ju‐Mei Wang, Ao‐Qiang Zhai, Fu‐yu Li, Hai‐jie Hu Cancer Medicine.2025;[Epub] CrossRef
Harnessing the microbiota-gut–brain axis to prevent and treat pediatric neurodevelopmental disorders: translational insights and strategies Shamma H. Alkuwaiti, Jurga Skrabulyte-Barbulescu, Lidya K. Yassin, Saif Almazrouei, Dana Aldhaheri, Mahra Alderei, Shamsa BaniYas, Shamsa H. Alshamsi, Abeer Alnuaimi, Sara Saeed, Mohammad Alawadhi, Paulina Rutkowska-Gauvry, Fatima Y. Ismail, Mohammad I. K Journal of Translational Medicine.2025;[Epub] CrossRef
Gut microbiota–derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy Wenbin Luo, Ruoyun Li, Chaofan Pan, Changjiang Luo Frontiers in Immunology.2025;[Epub] CrossRef
Analyzing the gut liver axis: a dual role of the microbiome in the genesis, progression, and treatment of liver cell carcinoma Qianzhu Li, Yafang Liu Frontiers in Microbiology.2025;[Epub] CrossRef
Cross-platform assessment of short-form video quality on the gut–liver axis: informational integrity and engagement disparity Man Sun, Dan Zang, Jun Chen Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
The Dual Role of Gut Microbiota and Their Metabolites in Hepatocellular Carcinoma: A Context-Dependent Framework Shuyu Zuo, Junhui Ma, Xue Li, Zhengyang Fan, Xiao Li, Yingen Luo, Lei Su Microorganisms.2025; 14(1): 73. CrossRef
Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan
Clin Mol Hepatol 2025;31(Suppl):S94-S111. Published online November 28, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as obesity and type 2 diabetes mellitus. This spectrum of liver disease ranges from isolated steatosis to more severe forms such as steatohepatitis, fibrosis, and cirrhosis. Recent studies highlight the role of gut microbiota in MASLD pathogenesis, showing that dysbiosis significantly impacts metabolic health and the progression of liver disease. This review critically evaluates current microbiome-centered therapies in MASLD management, including prebiotics, probiotics, synbiotics, fecal microbiota transplantation, and emerging therapies such as engineered bacteria and bacteriophage therapy. We explore the scientific rationale, clinical evidence, and potential mechanisms by which these interventions influence MASLD. The gut-liver axis is crucial in MASLD, with notable changes in microbiome composition linked to disease progression. For instance, specific microbial profiles and reduced alpha diversity are associated with MASLD severity. Therapeutic strategies targeting the microbiome could modulate disease progression by improving gut permeability, reducing endotoxin-producing bacteria, and altering bile acid metabolism. Although promising, these therapies require further research to fully understand their mechanisms and optimize their efficacy. This review integrates findings from clinical trials and experimental studies, providing a comprehensive overview of microbiome-centered therapies’ potential in managing MASLD. Future research should focus on personalized strategies, utilizing microbiome features, blood metabolites, and customized dietary interventions to enhance the effectiveness of these therapies.
Citations
Citations to this article as recorded by
Probiotic-Derived Strain-Specific Metabolites Ameliorate Metabolic Dysfunction–Associated Steatotic Liver Disease through Modulation of the Gut-Liver Axis Sang Jun Yoon, Jieun Choi, Sung-Min Won, Jeong Seok Yu, Hee Young Kim, Hyun Chae Joung, In Gyu Park, Jung A Eom, Sang Hak Han, Do Yup Lee, Ki Tae Suk Probiotics and Antimicrobial Proteins.2026; 18(3): 4353. CrossRef
Sarcopenia and MASLD: novel insights and the future Chang-Hai Liu, Qing-Min Zeng, Won Kim, Seung Up Kim, Zobair M. Younossi, Giovanni Targher, Christopher D. Byrne, Christos S. Mantzoros, Phunchai Charatcharoenwitthaya, Isabelle Anne Leclercq, Manuel Romero-Gómez, Hong Tang, Ming-Hua Zheng Nature Reviews Endocrinology.2026; 22(3): 139. CrossRef
Digoxin-induced gut dysbiosis: Mechanistic links to prostaglandin dysregulation and lipid metabolic imbalance Nila Ganamurali, Sarvesh Sabarathinam Prostaglandins & Other Lipid Mediators.2026; 182: 107055. CrossRef
Guideline comparison for fatty liver disease: European (EASL-EASD-EASO) and Asian (APASL) perspectives Ludovico Abenavoli Expert Review of Gastroenterology & Hepatology.2026; 20(1): 5. CrossRef
The Metabolic Dysfunction–Associated Steatotic Liver Disease–CKD Axis: Intersecting Pathways and Opportunities for Early Intervention Sriram Sriperumbuduri, Prathab Balaji Saravanan, Gaurav Gupta, Arun J. Sanyal Kidney International Reports.2026; 11(4): 103757. CrossRef
Exercise-mimicking effects of betaine in chronic disease prevention and management Yuhui Xu, Jianhong Gao, Minghui Wang, Hu Zhang Frontiers in Nutrition.2026;[Epub] CrossRef
Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host–microbe signaling and highlights 2-hydroxyisocaproate as a potential effector Jiyi Choi, Moon Gyeong Yoon, Se Ha Jang, Geum Ok Baek, Hyun Sun Jung, Na-Rae Lee, Choong Hwan Lee, Ji Eun Han, Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim Clinical and Molecular Hepatology.2026; 32(1): 239. CrossRef
The Gut Commensal Butyricimonas Virosa Modulates Gut Microbiota‐Dependent Thiamine Metabolism and Attenuates Mouse Steatotic Liver Disease Ningning He, Haoyu Wang, Zizhen Yang, Hui Li, Bei Liu, Kaiwei Chen, Zhinan Wu, Xinnan Zhao, Hewei Liang, Mengmeng Wang, Xiaofang Li, Yiyi Zhong, Haifeng Zhang, Liang Xiao, Karsten Kristiansen, Jixing Peng, Yuanqiang Zou, Shangyong Li Advanced Science.2026;[Epub] CrossRef
The Gut–Liver Axis in MASLD: From Host–Microbiome Crosstalk to Precision Therapeutics Ji Zhou, Bowen Zhu, Ziqian Bing, Tingting Wang, Yue Zhao Microorganisms.2026; 14(2): 471. CrossRef
Therapeutic modulation of the gut-liver axis with faecalibacterium prausnitzii in metabolic dysfunction-associated steatohepatitis Han Chen, Yan Wang, Wei Su, Yicheng Liu, Shuo Li, Yun Liu, Xiaoying Zhou BMC Microbiology.2026;[Epub] CrossRef
MetALD at the crossroads of metabolic and alcohol-related liver disease Gustavo Ayares, Luis Antonio Díaz, Juan Pablo Arab, Marco Arrese Trends in Endocrinology & Metabolism.2026;[Epub] CrossRef
Prebiotic modulation of FMT donor microbiota enhances MASLD-relevant taxa and functions in an in vitro gut model Kait F Al, Suyang Jia, Michael Silverman, Gregor Reid, Jeremy P Burton, Seema Nair Parvathy Journal of Applied Microbiology.2026;[Epub] CrossRef
Association of gut microbiota dietary index with MAFLD and the risk of liver fibrosis: the mediating effect of vitamins Jinlu Han, Teng Zhou, Jiong Chen, Ling Xu, Wen Shan, Qinghui Zhang Journal of Nutritional Science.2026;[Epub] CrossRef
The Microbiome‐Gut‐Liver Axis Drives Post‐Kasai Fibrosis in Biliary Atresia: From Mechanism to Precision Intervention Jiwen Cheng Hepatology Research.2026; 56(5): 648. CrossRef
Effects of Probiotic and Synbiotic Supplementation on Metabolic and Hepatic Outcomes in Children and Adolescents With Obesity, Including Those With Obesity‐Related Metabolic Dysfunction–Associated Steatotic Liver Disease: A Systematic Review and Meta‐Anal Pedram Pam, Mohammad Safari, Ali Hojati, Rasoul Zarrin, Amir Hossein Faghfouri Journal of Paediatrics and Child Health.2026; 62(5): 678. CrossRef
Correspondence to letter to the editor on “Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease” Eiji Kakazu, Masaaki Mino, Tatsuya Kanto Clinical and Molecular Hepatology.2026; 32(2): e235. CrossRef
Gut microbiome and metabolic health: mechanisms and precision interventions Zhengrui Li, Sudeshna Samui, Ji'an Liu, Yang Yang, Xue Liu, Qingyu Chen, Jing Li, Divya Gopinath, Peng Luo, Dan Shan Gut Microbes.2026;[Epub] CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Microbial dysbiosis in metabolic disorders: linking epigenomic regulation and pathological mechanisms Arun K. Sharma, Md Sayeed Akhtar, Khalid Orayj, Sadaf Farooqui, Abida Khan, Gunjan Sharma Drug Discovery Today.2026; 31(4): 104698. CrossRef
Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications Yinan Zhao, Ziyan Li, Guoying Yu Frontiers in Nutrition.2026;[Epub] CrossRef
Maternal-Infant Gut Microbiota Transmission and the Early Origins of Metabolic Liver Diseases: Mechanisms and Interventional Opportunities Xinrui Meng, Xueping Wu, Huihui Sun, Jing Cong, Yuchao Gu Nutrition Reviews.2026;[Epub] CrossRef
The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets Poonam Sahu, Trilochan Satapathy Probiotics and Antimicrobial Proteins.2026;[Epub] CrossRef
Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation Carlo Acierno, Alfredo Caturano, Fannia Barletta, Luca Rinaldi, Ferdinando Carlo Sasso, Luigi Elio Adinolfi, Riccardo Nevola Nutrients.2026; 18(11): 1765. CrossRef
Structural characterization of the pectic polysaccharide from corn silk and its protective mechanism against MASLD via regulation of the gut-liver axis Haichao Wang, Jiajing Yan, Haolin Jia, Xiaoyan Li, Bingxuan Li, Xuefang Zhang, Shujun Wang, Zheng Li, Yuhong Liu, Yifei Bian Carbohydrate Polymers.2026; : 125510. CrossRef
Association between oral microbiome alpha and beta diversity and MASLD risk: a large-scale, population-based retrospective study Zeru Liu, Yizhi Mao, Lei Zhang, Beibei Wang, Jiaxuan Tian, Yanjun Li, Shuangshuang Li, Yinglong He, Meiyan Zeng, Pan Meng, Houpan Song Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Association of prebiotic/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials in the context of prediction, prevention, and a personalized medicine framework Senlin Wang, Ruimin Zhang, Peisen Guo, Huawu Yang, Yanjun Liu, Hongmei Zhu EPMA Journal.2025; 16(1): 183. CrossRef
Deciphering the role of dietary modifications and gut dysbiosis in Non-Alcoholic Fatty Liver Disease Meenakshi Vachher, Kohinoor Kaur, Manisha Marothia, Archana Burman, Deepanjana, Savita Bansal Human Nutrition & Metabolism.2025; 40: 200305. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso Exploration of Medicine.2025;[Epub] CrossRef
Electroacupuncture Attenuates Intestinal Barrier Disruption via the α7nAChR-Mediated HO-1/p38 MAPK/NF-κB Pathway in a Mouse Model of Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized, Single-Blind, Controlled Trial Xiao Wang, Jiasen Sun, Peng Wang, Yimin Zhang, Jiuyang Chang, Zhijun Duan Biomedicines.2025; 13(4): 802. CrossRef
Unraveling MASLD: The Role of Gut Microbiota, Dietary Modulation, and AI-Driven Lifestyle Interventions Carolina Jiménez-González, Marta Alonso-Peña, Paula Argos Vélez, Javier Crespo, Paula Iruzubieta Nutrients.2025; 17(9): 1580. CrossRef
Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies Claudia Reytor-González, Daniel Simancas-Racines, Martín Campuzano-Donoso, Janeth Castano Jimenez, Náthaly Mercedes Román-Galeano, Gerardo Sarno, Evelyn Frias-Toral Food and Agricultural Immunology.2025;[Epub] CrossRef
Gut microbiota modulation by Traditional Chinese Medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease Ting Zhou, Ziwen Jin, Rilei Jiang, Weiwei Li Frontiers in Pharmacology.2025;[Epub] CrossRef
Orchestration of Gut–Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation Ao Liu, Mengting Huang, Yuwen Xi, Xiaoling Deng, Keshu Xu Biomedicines.2025; 13(6): 1422. CrossRef
Gut microbiota in liver diseases: initiation, development and therapy Jian-Xiu Yu, Jun Wu, Xin Chen, Su-gang Zang, Xue-bin Li, Li-Pei Wu, Shi-hai Xuan Frontiers in Medicine.2025;[Epub] CrossRef
Medical Implications of Renaming Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Yu-Jin Choi, Chang-Gue Son Journal of Korean Medicine.2025; 46(2): 40. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives Wenchu Qian, Ling He, Chenxue Fu, Tiantian Zeng, Hanyu Wang, Haifang Li Exploration of Digestive Diseases.2025;[Epub] CrossRef
Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD Zhonghao Jiang, Baolin Qian, Tongjie Xu, Junjie Bai, Wenguang Fu ImmunoTargets and Therapy.2025; Volume 14: 719. CrossRef
Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang Gut and Liver.2025; 19(4): 479. CrossRef
Association of the dietary index for gut microbiota and dietary inflammation index with metabolic dysfunction-associated steatotic liver disease and metabolic alcohol-associated liver disease Wenhao Wu, Zebin Hou Frontiers in Immunology.2025;[Epub] CrossRef
Cholesterol and the gut-liver axis: unraveling their role in the onset and progression of metabolic-associated steatotic liver disease Luis A. Rodríguez-Rojas, Leticia Bucio-Ortiz, Verónica Souza-Arroyo, María Concepción Gutiérrez-Ruiz, Luis E. Gómez-Quiroz, Roxana U. Miranda-Labra Exploration of Digestive Diseases.2025;[Epub] CrossRef
Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies Said A Al-Busafi, Ahmed Alwassief, Ali Madian, Hassan Atalla, Mohamed Alboraie, Ashraf Elbahrawy, Mohammed Eslam World Journal of Hepatology.2025;[Epub] CrossRef
Present and Future Perspectives in the Treatment of Liver Fibrosis Lucia Cerrito, Linda Galasso, Jacopo Iaccarino, Alessandro Pizzi, Fabrizio Termite, Giorgio Esposto, Raffaele Borriello, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco Pharmaceuticals.2025; 18(9): 1321. CrossRef
Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway Jianping Zhu, Yuzhen Chen, Yidi Han, Ji Li, Fahrul Nurkolis PLOS One.2025; 20(9): e0331303. CrossRef
Genome-Based Mexican Diet Bioactives Target Molecular Pathways in HBV, HCV, and MASLD: A Bioinformatic Approach for Liver Disease Prevention Leonardo Leal-Mercado, Arturo Panduro, Alexis José-Abrego, Sonia Roman International Journal of Molecular Sciences.2025; 26(18): 8977. CrossRef
Impact of non-alcoholic hepatic steatosis on prognosis and clinical outcomes in gastric cancer patients undergoing laparoscopic distal gastrectomy Yi-Fan Zou, Yi-Gang Zhang, Zi-Chu Zhao, Zheng Li, Hong-Da Liu, Qing-Ya Li, Ze-Tian Chen, Cheng-Jun Zhu, Hai-Tao Liu, Ji-Wei Wang, Feng-Yuan Li, Lin-Jun Wang, Dian-Cai Zhang, Li Yang, Hao Xu, Ze-Kuan Xu, Sen Wang World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
Recent research advances in RNA m5C methylation modification in liver diseases Wenjuan Chen, Lifan Zhang, Xinyu Gu, Yafeng Liu, Shujun Zhang, Xinjun Hu, Penghui Li Frontiers in Molecular Biosciences.2025;[Epub] CrossRef
Integrative gut microbiota and metabolomics reveals the mechanism of chicory extract in improving metabolic dysfunction-associated steatotic liver disease via gut-liver axis Haifeng Wang, Songlin Liu, Yonggang Chen, Weiwei Fang, Ying Cheng, Zhigang Zhang, Haiming Hu, Baifei Hu, Hongtao Liu Phytomedicine.2025; 148: 157404. CrossRef
Harnessing Gut Microbiome–Brain–Liver Crosstalk: Novel Therapeutic Strategies for Metabolic Dysfunction‐Associated Steatotic Liver Disease Xingtao Zhao, Ruolan Li, Jingdong Zhao, Ruiqi Sun, Shuo Zhang, Qiong Pan, Hongyan Lu, Jin Chai Medicine Bulletin.2025; 1(2): 136. CrossRef
Honeysuckle-derived exosome-like nanovesicles ameliorate metabolic-associated fatty liver disease by modulating gut microbiota and its metabolites Ping Li, Qingyuan Wu, Yuanhao Zhou, Xiaojuan Hu, Yan Tang, Yuanyuan Wang, Weijiao Fan, Yiyi Shan, Kexin Yu, Jie Wang, Shibing Wang, Xiao Ye, Huiyu Liu, Xiaozhou Mou Nano Research.2025; 18(12): 94907986. CrossRef
Perturbed microbial ecology in pediatric systemic lupus erythematosus: Evidence from the gut microbiome and serum metabolome Bo Li, Tao Ma, Yanjun Jia, Chunfeng Mou, Meng Zeng, Jie Yu, Lin Zou, Xiaoqiang Li, Han Wang Genes & Diseases.2025; : 101932. CrossRef
The Gut-Liver Axis: Molecular Mechanisms and Therapeutic Targeting in Liver Disease Liang Ma, He Wang, Qiuyu Jin, Zhiwen Sun, Shuang Yu, Yang Zhang International Journal of General Medicine.2025; Volume 18: 7531. CrossRef
Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD Xiaoxue Long, Hui Wang, Yuwei Lu, Xiaojing Gao, Yuanyuan Xiao, Mingliang Zhang, Jingyi Guo, Jingyi Yang, Ruiqi Zhang, Qian Li, Guiyun Zhou, Ruibao Yang, Feng Chen, Qingqing Wu, Liming Sun, Chengshuang Chu, Xuexue Zhu, Zhengjun Wu, Quanlu Ren, Chunping You Cell Metabolism.2025; 37(12): 2342. CrossRef
Gut microbiota in hepatic encephalopathy: a 3PM-guided three-tier health strategy Jing Chen, Mingliao Niu, Longjiang Zhang EPMA Journal.2025; 17(1): 135. CrossRef
An umbrella meta-analysis of microbial therapy on hepatic steatosis, fibrosis, and liver stiffness in metabolic dysfunction-associated steatotic liver disease Gvzalnur Kurban, Xiangjun Chen, Xingyi Jin, Hui Xia, Shaokang Wang, Guiju Sun Frontiers in Nutrition.2025;[Epub] CrossRef
Drug treatment of MASH from none to (too) many options? Amedeo Lonardo, Ralf Weiskirchen Exploration of Medicine.2025;[Epub] CrossRef
Prebiotic and Probiotic Foods in MASLD: Microbiome-Mediated Therapeutic Strategies Cui Beiming, Liu Yujie, Hui-Eun Chang Joyce, Chen Jieying, Xu Jiahang, Teoh Jian-Peng, Loong Ho Chun Synthetic Biology and Engineering.2025; 3(4): 10018. CrossRef
Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the bacterial metabolism of dietary substrates, modification of host molecules (such as bile acids [BAs], trimethylamine-N-oxide, and short-chain fatty acids), or products directly derived from bacteria. Recent studies have provided new insights into the association between MASLD and the risk of developing chronic kidney disease (CKD). Furthermore, alterations in microbiota composition and metabolite profiles, notably altered BAs, have been described in studies investigating the association between MASLD and the risk of CKD. This narrative review discusses alterations of specific classes of metabolites, BAs, fructose, vitamin D, and microbiota composition that may be implicated in the link between MASLD and CKD.
Citations
Citations to this article as recorded by
Radish Green Extract Attenuates Western Diet-Induced Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice Hye-Bin Lee, Yu Ra Lee, Eunjung Lee, Seong Un Jeong, Jae-Hyun Yoon, Miri Park, Yoonsook Kim, Ho-Young Park Journal of Agricultural and Food Chemistry.2026; 74(1): 874. CrossRef
Multi-omics reveal the key role of gut microbiota metabolism in adenine-induced chronic kidney disease Yijing Xin, Hui Ma, Xiang Li, Ruiyang Sun, Luo Fang, Libin Pan Toxicology and Applied Pharmacology.2026; 509: 117754. CrossRef
Research Progress on the Bile Acid Metabolome in Arteriovenous Fistula Stenosis among Maintenance
Hemodialysis Patients 佩 张 Advances in Clinical Medicine.2026; 16(03): 2204. CrossRef
Creatinine clearance rate predicts all-cause and cardiovascular mortality in patients with MASLD: a Shanghai cohort study Yingqi Hou, Yanqiu Huang, Chenghao Zhang, Wen Gu, Yadan Xu, Shuli Li, Jugang Wu, Jibin Liu, Honglin Liu Frontiers in Medicine.2026;[Epub] CrossRef
Plasma proteome profiling identifies XPNPEP3 as a novel biomarker associated with metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus Hua Ji, Yating Lu, Yichang Liu, Yinguang Jia, Jie Liu, Datong Deng, Mingwei Chen Annals of Medicine.2026;[Epub] CrossRef
Loss of immunometabolic adaptability in MASH: gut-derived signals drive macrophage reprogramming and fibrosis Yan Li, Yuyuan Hu, Yuan He, Yuhang Yang, Dingwen Xue, Erkui Xue, Jinghan Jia, Wei Zhang, Jinxi Wang Frontiers in Immunology.2026;[Epub] CrossRef
Ferroptosis in MASLD: From molecular mechanisms to therapeutic opportunities Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Wei Xie, Qin-Fen Chen, Yuxing Dong, Fudi Wang, Daolin Tang, Ming-Hua Zheng Med.2026; : 101099. CrossRef
Classification of intestinal inflammation driven by gut microbiota metabolites: a new paradigm for precision treatment of cardiovascular diseases Dahua Zhao, Yanjun Cui, Zhen Hua Frontiers in Microbiology.2026;[Epub] CrossRef
Bile Acids and the Gut–X Axis: TCM-Mediated Systemic Protection and Therapeutic Opportunities for Multi-Organ Diseases Jialu He, Linjie Qin, Xian Sun Metabolites.2026; 16(6): 366. CrossRef
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges Dario Piatto, Delia De Biasio, Francesco Giustino Cesaro, Gianmario Forcina, Vittoria Frattolillo, Antonio Colucci, Fabio Lamberti, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Journal of Clinical Medicine.2025; 14(11): 3911. CrossRef
Altered mitochondrial function: a clue therapeutic strategies between metabolic dysfunction-associated steatotic liver disease and chronic kidney disease? Jiang Bai, Lijuan Zhang, Letian He, Yun Zhou Frontiers in Nutrition.2025;[Epub] CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi Nutrients.2025; 17(13): 2211. CrossRef
Quyu Huazhuo Decoction alleviates non-Alcoholic steatohepatitis via remodeling the gut microbiota and regulating bile acid and short-chain fatty acid metabolism Lu Lu, Chengting Wu, Juhong Jia, Yuanqin Du, Yujiao Peng, Hongna Huang, Jingjing Huang, Yaobin Nong Journal of Chromatography B.2025; 1267: 124784. CrossRef
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano Exploration of Medicine.2025;[Epub] CrossRef
Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications Wenhua Bai, Zheng Zhu Frontiers in Endocrinology.2025;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis are Associated with Advanced Cardiovascular-Kidney-Metabolic Syndrome in Chinese and US Populations Shidi Hu, Dongmei Wang, Qingtao Yu, Zhi Chen, Weiguo Lu, Yuan Meng, Xuetao Peng, Lan Liu, Heng Wan, Jie Shen Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 4699. CrossRef
Two major causes of steatohepatitis are alcohol and metabolic syndrome. Although the underlying causes of alcoholrelated liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) differ, there are certain similarities in terms of the mode of disease progression and underlying pathophysiological mechanisms. Further, excessive alcohol consumption is often seen in patients with metabolic syndrome, and alcoholic hepatitis exacerbation by comorbidity with metabolic syndrome is an emerging clinical problem. There are certain ethnic differences in the development of both NAFLD and ALD. Especially, Asian populations tend to be more susceptible to NAFLD, and genetic polymorphisms in patatin-like phospholipase domain-containing 3 (PNPLA3) play a key role in both NAFLD and ALD. From the viewpoint of pathophysiology, cellular stress responses, including autophagy and endoplasmic reticulum (ER) stress, are involved in the development of cellular injury in steatohepatitis. Further, gutderived bacterial products and innate immune responses in the liver most likely play a profound role in the pathogenesis of both ALD and NASH. Though the recent progress in the treatment of viral hepatitis has reduced the prevalence of viral-related development of hepatocellular carcinoma (HCC), non-viral HCC is increasing. Alcohol and metabolic syndrome synergistically exacerbate progression of steatohepatitis, resulting in carcinogenesis. The gut-liver axis is a potential therapeutic and prophylactic target for steatohepatitis and subsequent carcinogenesis.
Citations
Citations to this article as recorded by
Biologically Intact Therapeutic Exosomes From Human Hepatic Progenitor Cells for Liver Diseases Taewoon Kim, Gul Karima, Luke P. Lee, Jong Wook Hong Advanced Healthcare Materials.2026;[Epub] CrossRef
Chronic co-exposure to BPA and alcohol synergizes hepatotoxicity via dysregulation of glycerolipid metabolism and ceramide/HtrA2-driven apoptosis in HepG2 cells Yan Qin Tan, Chia-Lung Shih, Yi-Chia Chen, Sheng-Han Lee, Ji-Rui Yang, Chan-Yen Kuo, Yi-Shiou Chiou Journal of Hazardous Materials.2026; 504: 141290. CrossRef
Current status and unresolved issues in early chronic pancreatitis Akira YAMAMIYA, Atsushi IRISAWA Suizo.2026; 41(1): 9. CrossRef
Steatotic liver disease: a dynamic spectrum, not a static state CW Spearman South African Journal of Gastroenterology and Hepatology.2026; 3(1): 22. CrossRef
Polygonatum cyrtonema Polysaccharides‐Derived Metabolic Meta Alleviates ALD via a Gut–Liver Axis–Mediated, Bifidobacterium pseudolongum–Driven Suppression of the AA Metabolism–MAPK Signaling Network Xingcai Gao, Qing Zhou, Baoting Liu, Jun Li, Jianhua Xie, Yi Chen, Chenxu Gong, Xiaobo Hu, Qiang Yu Food Frontiers.2026;[Epub] CrossRef
Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial Hiroo Fukada, Kazuyoshi Kon, Reiko Yaginuma, Akira Uchiyama, Maki Morinaga, Kei Ishizuka, Kyoko Fukuhara, Hironao Okubo, Satoko Suzuki, Shuko Nojiri, Shunhei Yamashina, Kenichi Ikejima Frontiers in Medicine.2025;[Epub] CrossRef
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective Zobair M. Younossi, Homie Razavi, Michael Sherman, Alina M. Allen, Quentin M. Anstee, Kenneth Cusi, Scott L. Friedman, Eric Lawitz, Jeffrey V. Lazarus, Detlef Schuppan, Manuel Romero‐Gómez, Jörn M. Schattenberg, Miriam B. Vos, Vincent Wai‐Sun Wong, Vlad R Alimentary Pharmacology & Therapeutics.2025; 61(9): 1467. CrossRef
Multi-Cohort Exploration of Repetitive Element Transcription and DNA Methylation in Human Steatotic Liver Disease Neil A. Youngson, Aikaterini Tourna, Timothy Chalmers, Kelly V. Prates, Josepmaria Argemi, Ramon Bataller, Koroush S. Haghighi, Lindsay E. Wu, Shilpa Chokshi, Peter Starkel, Patrick S. Western, Margaret J. Morris, Stephen M. Riordan International Journal of Molecular Sciences.2025; 26(12): 5494. CrossRef
Letter to the Editor: Metabolic dysfunction‐associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality Hong‐Xia Li, Zhi‐Qin Xie, Zhao‐Ming Yang, Cai‐Xi Tang Hepatology.2023; 77(4): E67. CrossRef
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro Hepatology Research.2023; 53(2): 104. CrossRef
Non-alcoholic fatty liver disease: Definition and subtypes Seul Ki Han, Soon Koo Baik, Moon Young Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S5. CrossRef
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways” Seung Min Lee, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef
Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease Xiaoqin Wu, Xiude Fan, Tatsunori Miyata, Adam Kim, Christina K. Cajigas-Du Ross, Semanti Ray, Emily Huang, Moyinoluwa Taiwo, Rakesh Arya, Jianguo Wu, Laura E. Nagy Annual Review of Pathology: Mechanisms of Disease.2023; 18(1): 411. CrossRef
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease Georg Semmler, Christian Datz, Michael Trauner Clinical and Molecular Hepatology.2023; 29(Suppl): S244. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease Hyunwoo Oh, Won Sohn, Yong Kyun Cho Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Non-alcoholic fatty liver disease: the pathologist’s perspective Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef
Therapeutic targets in alcohol-associated liver disease: progress and challenges Ayooluwatomiwa Deborah Adekunle, Adeyinka Adejumo, Ashwani K. Singal Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation Sara Novi, Vincenzo Vestuto, Pietro Campiglia, Nicola Tecce, Alessia Bertamino, Mario Felice Tecce Nutrients.2023; 15(12): 2748. CrossRef
Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu Clinical and Molecular Hepatology.2023; 30(1): 80. CrossRef
Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Diabetologia.2022; 65(3): 518. CrossRef
Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: Evidence from mediation analysis Mi Na Kim, Chun-Han Lo, Kathleen E. Corey, Xiao Luo, Lu Long, Xuehong Zhang, Andrew T. Chan, Tracey G. Simon Clinical Nutrition.2022; 41(2): 356. CrossRef
Changes in general and central fatness are associated with hepatocellular carcinoma: A Korean nationwide longitudinal study Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Seong Gyu Hwang International Journal of Cancer.2022; 150(10): 1587. CrossRef
Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease Maki Morinaga, Kazuyoshi Kon, Akira Uchiyama, Hiroo Fukada, Kyoko Fukuhara, Reiko Yaginuma, Eisuke Nakadera, Shunhei Yamashina, Kenichi Ikejima Hepatology International.2022; 16(2): 348. CrossRef
Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis Seunghwan Shin, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Diagnostics.2022; 12(2): 441. CrossRef
Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study Chan-Young Jung, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim Diabetes & Metabolism.2022; 48(4): 101344. CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study Chan-Young Jung, Ho Soo Chun, Minjong Lee, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim Diabetes & Metabolism.2022; 48(5): 101362. CrossRef
Natural History of Alcohol-Associated Liver Disease: Understanding the Changing Landscape of Pathophysiology and Patient Care Jasmohan S. Bajaj, Laura E. Nagy Gastroenterology.2022; 163(4): 840. CrossRef
Alcohol use patterns and risk of incident cataract surgery: a large scale case–control study in Japan Kota Fukai, Ryo Terauchi, Yuko Furuya, Kei Sano, Shoko Nakazawa, Noriko Kojimahara, Keika Hoshi, Tadashi Nakano, Akihiro Toyota, Masayuki Tatemichi Scientific Reports.2022;[Epub] CrossRef
Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives Yoonji Ha, Inju Jeong, Tae Hyun Kim Biomedicines.2022; 10(10): 2530. CrossRef
Genome-Scale Metabolic Modeling Reveals Sequential Dysregulation of Glutathione Metabolism in Livers from Patients with Alcoholic Hepatitis Alexandra Manchel, Radhakrishnan Mahadevan, Ramon Bataller, Jan B. Hoek, Rajanikanth Vadigepalli Metabolites.2022; 12(12): 1157. CrossRef
The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma Tomomi Kogiso, Katsutoshi Tokushige Cancers.2021; 13(3): 516. CrossRef
Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease Hee Kyung Shin, Jeong Hwan Park, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Jin-Woo Lee, Won Kim Scientific Reports.2021;[Epub] CrossRef
Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus Kiyoung Lim, Minkyu Kang, Junggil Park Nutrients.2021; 13(10): 3400. CrossRef
First
Prev
